← 返回

从实验室到救命疗法:CAR-T 细胞治疗在肿瘤学中的崛起

英文原题:From lab to lifesaver: the rise of CAR T-cell therapy in oncology.

查看英文原题

From lab to lifesaver: the rise of CAR T-cell therapy in oncology.

PubMed 2025/05/16(内容时间) J Egypt Natl Canc Inst Q3 · IF 2.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本文概述了 CAR-T 细胞治疗与其他治疗方式整合的未来展望,以及探索针对患者个体的方案以变革肿瘤诊疗。

中文摘要

近年来,随着免疫疗法,尤其是嵌合抗原受体(CAR)T细胞疗法问世,癌症治疗模式发生了显著变化。尽管该疗法治疗血液系统恶性肿瘤取得突破性积极结局,但严重毒性、治疗费用高及实体瘤疗效有限等挑战仍然存在。本综述强调这些局限及CAR-T 细胞疗法持续创新的必要性。正文:本文全面综述CAR-T 细胞疗法的最新进展,重点介绍其免疫治疗原理、如何修饰T细胞以用于靶向癌症治疗,以及临床应用。本文探讨CAR-T 细胞疗法的关键组成,包括使T细胞与癌细胞相互作用并发挥细胞毒效应的抗原识别结构域和胞内信号结构域。综述已获批疗法和正在开展的临床试验,并介绍细胞因子释放综合征(CRS)、神经毒性及抗原逃逸机制等障碍。此外,本文讨论前沿CAR-T 疗法的创新和个体化治疗策略,强调提升安全性和疗效。

本文展望将CAR-T 细胞疗法与其他治疗整合,并探索患者特异性治疗方法,以革新癌症治疗。综述旨在弥补现有研究空白,为生物医学和肿瘤学领域的学生与研究人员提供有价值见解。

展开英文摘要原文

Recently, cancer treatment paradigms have shifted dramatically with the advent of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapy. Despite it is revolutionary positive outcomes in treating hematologic malignancies, challenges such as severe toxicities, high treatment costs, and limited efficacy in solid tumors persist. This review highlights these limitations and the ongoing need for innovation in CAR T-cell therapy. MAIN BODY: This manuscript provides a comprehensive review of most current advancements in CAR T-cell therapy, with a focus on targeting its immunotherapeutic principles, modification of T cells for Targeted cancer therapy using T cells, and clinical applications. It explores the key elements of CAR T-cell therapy, containing antigen recognition domain and intracellular signaling domains, which enable T cells to interact with cancer cells and exert cytotoxic effects. The review examines approved therapies, and ongoing clinical trials, Along with obstacles like cytokine release syndrome (CRS), neurotoxicity, along antigen escape mechanisms. Furthermore, innovations in cutting-edge CAR T-cell therapies and personalized treatment approaches are discussed, together with an emphasis on improving safety and efficacy.

The manuscript outlines the future outlook on integrating CAR T-cell therapy integrated with other treatments and exploring patient-specific approaches to revolutionize cancer care. This review aims to bridge the existing gaps in research, offering valuable insights for students and researchers in biomedical sciences and oncology.

论文信息

作者
Jangavali SS、Hangargekar PB、Gangthade BU、Jadhav SA、Havelikar UA、Joshi AA
第一作者单位
Department of Pharmacy, ASPM's K. T. Patil College of Pharmacy, Dharashiv, 413501, Maharashtra, India.India
通讯作者单位
Department of Quality Assurance, ASPM's K. T. Patil College of Pharmacy, Dharashiv, 413501, Maharashtra, India. pallavibh10@gmail.com.India
文献类型
综述
期刊
Journal of the Egyptian National Cancer Institute2025 May 16
原文标识
PubMed 40377854 · DOI 10.1186/s43046-025-00262-6